Lahita's Systemic Lupus Erythematosus
- 6th Edition - July 23, 2021
- Imprint: Academic Press
- Editor: Robert G. Lahita
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 2 0 5 8 3 - 9
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 1 4 8 8 - 8
Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disorder that can affect virtually any organ of the body. In lupus, the body's immune system,… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteSystemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disorder that can affect virtually any organ of the body. In lupus, the body's immune system, which normally functions to protect against foreign invaders, becomes hyperactive, forming antibodies that attack normal tissues and organs, including the skin, joints, kidneys, brain, heart, lungs, and blood. Lupus is characterized by periods of illness, called flares, and periods of wellness or remission.
Because its symptoms come and go and mimic those of other diseases, lupus is difficult to diagnose. There is no single laboratory test that can definitively prove that a person has the complex illness.
To date, lupus has no known cause or cure. Early detection and treatment are the key to a better health outcome and can usually lessen the progression and severity of the disease. Anti-inflammatory drugs, antimalarials, and steroids (such as cortisone and others) are often used to treat lupus. Cytotoxic chemotherapies, like those used in the treatment of cancer, are also used to suppress the immune system in lupus patients.
A new edition of this established and well-regarded reference combines basic science with clinical science to provide a translational medicine model. Systemic Lupus Erythematosus, Sixth Edition, is a useful reference for specialists in the diagnosis and management of patients with SLE, a tool for measurement of clinical activity for pharmaceutical development and basic research of the disease, and a reference work for hospital libraries.
Because its symptoms come and go and mimic those of other diseases, lupus is difficult to diagnose. There is no single laboratory test that can definitively prove that a person has the complex illness.
To date, lupus has no known cause or cure. Early detection and treatment are the key to a better health outcome and can usually lessen the progression and severity of the disease. Anti-inflammatory drugs, antimalarials, and steroids (such as cortisone and others) are often used to treat lupus. Cytotoxic chemotherapies, like those used in the treatment of cancer, are also used to suppress the immune system in lupus patients.
A new edition of this established and well-regarded reference combines basic science with clinical science to provide a translational medicine model. Systemic Lupus Erythematosus, Sixth Edition, is a useful reference for specialists in the diagnosis and management of patients with SLE, a tool for measurement of clinical activity for pharmaceutical development and basic research of the disease, and a reference work for hospital libraries.
- Completely updated, revised, and expanded with the most comprehensive and accessible reference on SLE for clinicians and scientists
- Full-color presentation throughout the book
- Provides the latest information available on diagnosis and treatment
- Incorporates an international panel of authors who are experts in their fields, with an emphasis on young, cutting-edge scientists and physicians
Primary audience is basic scientists and clinicians who are interested in SLE including rheumatologists, dermatologists, nephrologists, immunologists and allergists
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Foreword
- Foreword from the First Edition
- Preface to Edition 6, Systemic Lupus Erythematosus
- Acknowledgment
- History of lupus erythematosus
- Basis of the disease
- Section A. Genetics and epigenetics
- Chapter 1. Major histocompatibility complex and SLE
- The MHC region
- Subregions of the MHC
- Evolution and gene clustering in the human MHC
- HLA polymorphism
- Extended linkage disequilibrium at the MHC
- Conserved extended haplotypes/ancestral haplotypes
- The sequence of the MHC
- Nomenclature of HLA and non-HLA alleles
- HLA class I molecules
- HLA class II molecules
- HLA-DRB gene haplotypes
- Genome-wide association studies and the MHC
- HLA typing by imputation
- MHC class III and the RCCX module
- The MHC region and SLE (HLA)
- The MHC region and SLE (complement)
- SNP-based MHC analyses in SLE
- Targeted SNP-based analysis
- GWAS and the MHC
- ImmunoChip and the MHC
- Combining SNPs with structural variation at the RCCX module
- Additional MHC associations with SLE
- The future…defining mechanisms
- Chapter 2. Lupus susceptibility genes
- Introduction
- Identifying SLE susceptibility genes
- Pleotropic effects of SLE risk loci
- SLE risk loci impact pathways involved in key immune processes
- The role of chromosome X in SLE
- Clinical translation of genetic findings
- Concluding remarks
- Chapter 3. Epigenetics in systemic lupus erythematosus and the integration of molecular pathways
- Introduction
- What is epigenetics?
- DNA methylation in SLE
- Epigenome-wide association studies for SLE
- Histone modification landscapes in SLE
- MicroRNA changes in SLE
- Epigenetics as an intermediary of genetic and environmental risk
- Lupus stratification based on molecular profiles
- Diagnostic and therapeutic implications of epigenetics
- Conclusions and future perspectives
- Section B. Immunopathogenesis
- Chapter 4. Autoantigens, antigenic mimicry, and immune complexes
- Autoantigens
- Antigenic mimicry
- Immune complex-mediated tissue damage
- Chapter 5. B-cell biology, tolerance, and autoantibodies
- Introduction
- B-cell tolerance
- B-cell activation pathways in lupus
- Multiple roles for B cells in SLE
- Plasma cell longevity in lupus and implications for therapeutic interventions
- Chapter 6. T-cell biology, tolerance, and regulation
- T-cell physiopathology in SLE
- Aberrant T-cell signaling in SLE
- Dysregulated T-cell activation in SLE
- Abnormal expression of T-cell-derived cytokines in SLE
- T-cell subsets in SLE
- CD4+ Tregs in SLE
- Impaired immune tolerance in SLE
- Therapeutic approaches to restore T-cell homeostasis in SLE
- Conclusions
- Chapter 7. Polymorphonuclear cells
- Introduction
- NETs and autoimmunity
- The role of neutrophils in the pathogenesis of SLE
- LDGs, NETs, and vascular damage in SLE
- Conclusion
- Chapter 8. Metabolic and mitochondrial dysfunction in SLE
- Introduction
- Metabolic pathways regulate proinflammatory immune responses via mTOR activation
- Mitochondrial dysfunction and oxidative stress underlie mTOR activation in SLE
- Metabolic checkpoints of pathogenesis are targets for treatment in SLE
- Conclusions
- Chapter 9. Immunopathogenesis: the role of mucosal and skin microbiota in SLE
- Introduction: microbiota-immune codependence
- Hygiene hypothesis and autoimmunity
- Importance of barrier function in autoimmunity with a focus on TLR7
- Bacterial commensals implicated in SLE
- Multistep pathogenesis involving the microbiota in lupus (genetics, epigenetics, and environmental influences on commensals)
- SLE-related pathobionts in other autoimmune diseases
- Section C. Disease effectors and modifiers
- Chapter 10. Complement and SLE
- Introduction
- Biology of the complement system
- Effector functions of the complement system
- Pathological consequences of complement dysregulation
- Complement deficiency and SLE
- Complement as biomarkers for SLE diagnosis and monitoring
- Complement-targeted therapeutics for SLE
- Summary
- Chapter 11. Interferons and cytokines in SLE pathogenesis and therapy
- Introduction
- The interferons
- Tumor necrosis factor family (TNF, BLyS)
- Interleukin-1 family
- Interleukin-2 family
- Interleukin-6
- Interleukin-17 family
- Macrophage migration inhibitory factor family
- Current challenges
- Chapter 12. Innate immunity in SLE pathogenesis
- Introduction
- Pattern recognition receptors
- Dendritic cells and SLE
- mDC in lupus
- Monocytes and inflammasomes in lupus
- Conclusion
- Chapter 13. Sex bias in SLE
- Estrogen
- Prolactin
- Progesterone
- Androgens
- Environment and sex hormones
- Genetic and epigenetic contributions to sex bias in SLE
- Sex chromosomes underlying sexual dimorphism of SLE
- Epigenetic regulation of the X chromosome and its implication in SLE
- Autosomal factors underlying female predisposition in SLE
- Crosstalk between hormonal and genetic/epigenetic factors
- Section D. Tissue injury—the biology
- Chapter 14. Mechanisms of tissue injury in lupus nephritis
- Introduction
- Pathogenic mechanisms of LN
- Conclusion
- Chapter 15. The skin
- Introduction
- Overview of subtypes of CLE
- Mechanisms of disease (lessons from murine and human studies)
- Summary
- Chapter 16. The brain in SLE: mechanisms and detection of injury and therapeutic strategies
- Introduction
- Diagnosis and epidemiology
- Genetic predisposition and environmental triggers
- Pathologic mechanisms and neuropathology
- Neuroimaging of the CNS
- Blood–brain barrier
- Animal models
- Microglia
- Maternal passage of antibodies
- Therapy: current and future
- Chapter 17. The role of infections in SLE pathogenesis
- Introduction
- Pathogens in the initiation of systemic lupus erythematosus
- Infections exacerbating SLE disease
- Potentially severe infections in SLE
- Parasitic infections and SLE models
- Conclusions
- Chapter 18. Tissue injury—the biology: SLE-associated vascular disease and antiphospholipid syndrome
- Systemic lupus erythematosus-associated vascular disease
- Antiphospholipid syndrome
- Clinical presentation of disease
- Section A. Clinical presentation
- Chapter 19. Epidemiology of SLE and related diseases: incidence, prevalence, and mortality
- Classification criteria
- Incidence
- Prevalence
- Mortality
- Cutaneous lupus erythematosus
- Antiphospholipid antibody syndrome
- Chapter 20. The clinical presentation of systemic lupus erythematosus and laboratory diagnosis
- Introduction
- General symptoms
- Musculoskeletal manifestations of lupus
- Clinical presentation of lupus of the skin
- Renal manifestations of lupus
- Clinical presentation of cardiovascular lupus
- Hematology of SLE
- Pulmonary disease and lupus
- Gastrointestinal manifestations of SLE
- Vasculitis in SLE
- Nervous system involvement in SLE
- The eye and SLE
- Miscellaneous organ involvement in SLE
- Classification criteria
- Chapter 21. Passively acquired lupus in the fetus and neonate
- Introduction
- Passively acquired cardiac-NL
- The transient skin rash
- Less commonly encountered manifestations of NL
- Candidate antigen–antibody systems in NL
- Proposed mechanisms of immune injury in cardiac-NL
- Murine model of cardiac-NL
- Genetics of NL child and the mother
- Maternal disease at identification of neonatal lupus and progression
- Factors contributing to mortality
- Treatment and prevention of cardiac-NL
- Conclusions
- Chapter 22. Systemic lupus erythematosus in children
- Introduction
- Presentation at diagnosis with childhood-onset SLE
- Mucocutaneous manifestations
- Musculoskeletal manifestations
- Hematologic manifestations/antiphospholipid antibody syndrome
- Neuropsychiatric manifestations
- Lupus nephritis
- Cardiovascular manifestations
- Gastrointestinal manifestations
- Pulmonary manifestations
- Biomarkers
- Immunogenetics of SLE
- Unique pediatric therapeutic considerations
- Puberty and contraception considerations
- Adherence
- Outcome measures/patient-reported outcomes
- Transition
- Conclusion
- Chapter 23. Environmental and drug-induced lupus
- Introduction
- Paradigm for etiology of autoimmunity and lupus
- Mechanisms
- Conclusions
- Chapter 24. Reproductive health
- Introduction
- Pregnancy
- SLE offspring
- Neonatal lupus
- Principles of SLE management in pregnancy: disease control with pregnancy-compatible medications
- Hydroxychloroquine
- Prednisone
- Azathioprine
- Tacrolimus and cyclosporin
- Aspirin
- Heparin and low-molecular weight heparin
- Biologics
- Lactation
- Fertility preservation with cyclophosphamide
- Reproductive health in men with SLE
- Chapter 25. Monitoring disease activity
- Introduction
- Measuring disease activity and severity
- Measuring clinical response
- Measuring disease flares
- Chapter 26. Overlap syndromes
- Introduction
- Rheumatoid arthritis/systemic lupus erythematosus overlap
- Sjogren's syndrome/systemic lupus erythematosus overlap
- Conclusion
- Section B. Specific organ involvement and clinical presentation
- Chapter 27. Nervous system
- Classification and attribution of nervous system disease in SLE
- Etiology of neuropsychiatric systemic lupus erythematosus
- Clinical manifestations of neuropsychiatric systemic lupus erythematosus
- Diagnosis of neuropsychiatric systemic lupus erythematosus
- Neuroimaging in neuropsychiatric systemic lupus erythematosus
- Treatment of neuropsychiatric events in patients with systemic lupus erythematosus
- Chapter 28. Skin
- Introduction
- Overview
- Subsets of cutaneous lupus erythematosus
- Lupus-nonspecific skin lesions
- Associated skin conditions
- Epidemiology/natural history
- Pathogenesis of cutaneous lupus erythematosus
- Measurement of outcomes
- Treatment
- Chapter 29. Kidney disease
- Introduction
- Epidemiology of lupus nephritis
- Diagnostic evaluation
- Treatment of lupus nephritis
- Conclusion
- Chapter 30. Cardiovascular disease in lupus
- Introduction
- Noncoronary cardiac disease in lupus
- Atherosclerotic cardiovascular disease in lupus
- Inflammation and the pathogenesis of atherosclerosis
- Traditional and SLE-specific risk factors for atherosclerosis in SLE
- Potential nontraditional biomarkers for atherosclerosis in SLE
- Strategies for prevention of cardiovascular complications in SLE
- Summary
- Chapter 31. Pulmonary manifestations of systemic lupus erythematosus
- Introduction
- Pleural disease
- Airway disease
- Parenchymal lung disease
- Pulmonary vascular disease
- Other
- Conclusion
- Chapter 32. GI hepatic and nonhepatic diseases
- Introduction
- Oral cavity
- Esophagus and stomach
- Small intestine and colon
- Liver and gallbladder
- Pancreas
- Conclusion
- Chapter 33. Musculoskeletal system: articular disease, myositis, and bone metabolism
- Arthralgias/Arthritis
- Tendon rupture
- Myalgia/myositis
- Osteonecrosis
- Osteoporosis
- Chapter 34. Clinical presentation of antiphospholipid syndrome
- Diagnostic approach to antiphospholipid syndrome
- Epidemiology
- Clinical features
- Chapter 35. Hematology: cytopenias
- Leukopenia
- Thrombocytopenia
- Anemia
- Chapter 36. Malignancy risk and screening
- Introduction
- Malignancy with increased risk in SLE
- Malignancy with decreased risk in SLE
- Conclusion
- Section C. Treatment of systemic lupus erythematosus
- Chapter 37. Antimalarial drugs (and lupus)
- Introduction
- Pharmacology and mechanisms of action
- Current use in lupus
- Hydroxychloroquine and reproductive health
- Metabolic effects of antimalarials
- Effects on thrombosis
- Antimalarials in experimental settings
- Safety, toxicity, and dosing guidelines
- Hydroxychloroquine monitoring
- Mepacrine
- Conclusions
- Chapter 38. Glucocorticoids
- Glucocorticoids
- Clinical use of glucocorticoids in SLE
- Glucocorticoid mechanisms of action in SLE
- Adverse effects of glucocorticoids
- Conclusion and future directions
- Chapter 39. Immunosuppressive therapy in SLE
- Introduction
- Cyclophosphamide
- Mycophenolate mofetil
- Belimumab
- Rituximab
- Azathioprine
- Methotrexate
- Leflunomide
- Abatacept
- Rituximab
- Baricitinib
- Dietary supplements
- Vitamin D
- Curcumin
- Omega-3 fatty acids
- Antioxidants
- Dietary supplementation to avoid
- Conclusion
- Chapter 40. Pipeline therapies and future drug development
- Introduction
- Adaptive immunity
- Innate immunity
- Combined adaptive and innate approaches: induction of tolerance
- Summary
- Chapter 41. Challenges of systemic lupus clinical trials
- Background
- Current SLE trial designs
- Within-subject heterogeneity
- Between-subject heterogeneity
- Protocol deviations and missing data
- Novel trial designs
- Conclusions
- Index
- Edition: 6
- Published: July 23, 2021
- Imprint: Academic Press
- No. of pages: 730
- Language: English
- Hardback ISBN: 9780128205839
- eBook ISBN: 9780323914888
RL
Robert G. Lahita
Dr. Robert Lahita is Clinical Professor of Medicine at Rutgers University, and the Director of the Institute for Autoimmune and Rheumatic Diseases. He is a fellow of the ACP and the Royal College, and a master of the ACR. Dr. Lahita is the author of more than 16 books and 150 scientific publications in the field of autoimmunity. He is the editor of the standard textbook Systemic Lupus Erythematosus and the Senior Editor of the Textbook of Autoimmunity, and the author of Lupus: Q and A for patients and Autoimmunity in Women.
Affiliations and expertise
Professor of Medicine, Adjunct Professor of Biochemistry and Molecular Biology UMDNJ, New Jersey Medical School Vice President and Chairman of Medicine Newark Beth Israel Medical Center Newark, NJ, USARead Lahita's Systemic Lupus Erythematosus on ScienceDirect